文献速递神经肌肉病

Fordadistrogene movaparvovec治疗可行走杜氏肌营养不良的3期CIFFREO研究

Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study.
PubMed 文献 · Lancet Neurol · 2026-01-01

基于疗效与安全性数据判定获益-风险为负,申办方已停止该基因治疗药物的进一步临床开发。

要点

  • fordadistrogene movaparvovec组不良事件发生率99%(78/79),安慰剂组77%(27/35)。
  • 基于疗效与安全性数据判定获益-风险为负,申办方已停止进一步临床开发。

核心结论

  • CIFFREO研究未达到主要疗效终点,fordadistrogene movaparvovec的获益-风险判定为负,申办方已停止该研究性基因治疗药物的进一步临床开发。

研究设计与样本

  • CIFFREO为3期双盲随机安慰剂对照研究,在澳大利亚、比利时、加拿大、法国、德国、以色列、意大利、日本、俄罗斯、韩国、西班牙、瑞士、台湾、英国和美国共45个学术与医院中心开展。
  • 纳入者为男性、可行走、年龄4岁至不足8岁、经基因诊断的杜氏肌营养不良患者。
  • 队列1第1天静脉给予fordadistrogene movaparvovec 2×10^14 vg/kg、第390天安慰剂;队列2第1天安慰剂、第390天给予fordadistrogene movaparvovec 2×10^14 vg/kg。
  • 主要终点为基线至第52周NSAA总分变化,在全分析集(随机分组且第1天接受单剂研究药物或安慰剂者,排除同胞及符合遗传排除标准者)中用重复测量混合模型分析,仅纳入完成1年随访者。

主要发现

  • 主要结局在fordadistrogene movaparvovec组64例和安慰剂组28例中分析。
  • 不良事件在fordadistrogene movaparvovec组为78/79(99%),安慰剂组为27/35(77%);严重不良事件分别为25例(32%)和5例(14%);研究无死亡。
  • fordadistrogene movaparvovec组较安慰剂组常见不良事件包括呕吐(60例[76%] vs 5例[14%])、发热(49例[62%] vs 3例[9%])、食欲下降(26例[33%] vs 1例[3%])、恶心(23例[29%] vs 3例[9%])、肝谷氨酸脱氢酶升高(19例[24%] vs 0例)、鼻咽炎(19例[24%] vs 6例[17%])和腹痛(17例[22%] vs 3例[9%])。

关键数值与推荐

  • 给药方案:fordadistrogene movaparvovec 2×10^14 vg/kg静脉给药。
  • 安全性:fordadistrogene movaparvovec组不良事件99%、严重不良事件32%,安慰剂组分别为77%和14%。
  • 研究结论:基于本3期研究疗效与安全性数据,fordadistrogene movaparvovec的获益-风险判定为负,申办方已停止进一步临床开发。

临床怎么用

  • 该研究未显示fordadistrogene movaparvovec在52周NSAA总分上优于安慰剂,不能据此支持其用于可行走杜氏肌营养不良男孩。
  • fordadistrogene movaparvovec组不良事件和严重不良事件发生率高于安慰剂组,常见呕吐、发热、食欲下降、恶心和肝谷氨酸脱氢酶升高。
  • 基于获益-风险判定为负,申办方已停止该研究性基因治疗药物的进一步临床开发,临床不应将其作为可用治疗选择。

局限性

  • 主要终点分析仅纳入完成1年随访者,fordadistrogene movaparvovec组64例、安慰剂组28例,样本量有限。
  • 研究纳入者为4岁至不足8岁可行走男孩,结论不能外推至其他年龄或不能行走患者。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gene transfer is a promising therapeutic approach for Duchenne muscular dystrophy as the disease results from mutations in a single gene. Fordadistrogene movaparvovec is an investigational recombinant adeno-associated virus 9 (rAAV9)-based vector encoding a mini-dystrophin transgene protein for Duchenne muscular dystrophy . We aimed to assess the safety and efficacy of fordadistrogene movaparvovec in slowing the functional decline experienced by individuals with Duchenne muscular dystrophy. METHODS: CIFFREO was a phase 3, double-blind, randomised, placebo-controlled study done at 45 academic and hospital sites in Australia, Belgium, Canada, France, Germany, Israel, Italy, Japan, Russia, South Korea, Spain, Switzerland, Taiwan, the UK, and the USA. Eligible participants were male, ambulatory, aged 4 years to younger than 8 years, with a genetic diagnosis of Duchenne muscular dystrophy. Participants were randomly assigned (2:1) using interactive response technology, stratified by age (<6 years or ≥6 years), to cohort 1 (intravenous fordadistrogene movaparvovec 2 × 1014 vector genomes [vg]/kg on day 1, placebo on day 390) or cohort 2 (placebo on day 1, intravenous fordadistrogene movaparvovec 2 × 1014 vg/kg on day 390). Placebo vials were provided and prepared identically to fordadistrogene movaparvovec. Participants, investigators, and outcome assessors were masked to treatment assignments. The primary endpoint was change from baseline to week 52 in the North Star Ambulatory Assessment (NSAA) total score, assessed in patients in the full analysis set (all participants who were randomly assigned and received a single dose of fordadistrogene movaparvovec or placebo on day 1, excluding siblings and those meeting genetic exclusion criteria), analysed using a mixed model for repeated measures. Participants were analysed according the cohort to which they were assigned and analysis only included participants who completed the 1-year follow-up. The safety analysis set comprised all participants who were randomly assigned and received a single dose of fordadistrogene movaparvovec or placebo on day 1. The trial was registered at ClinicalTrials.gov (NCT04281485) and is active, not recruiting. FINDINGS: Between Nov 5, 2020, and April 20, 2023, 226 participants were screened for eligibility, 122 of whom were randomly assigned (81 to cohort 1 and 41 to cohort 2). The primary outcome was analysed in 64 participants in the fordadistrogene movaparvovec group and 28 in the placebo group. At screening, mean age was 6·3 years (SD 1·3) in participants in the fordadistrogene movaparvovec group and 6·5 years (1·2) in participants in the placebo group; mean NSAA total score was 22·5 (SD 3·6) in the fordadistrogene movaparvovec group and 23·5 (3·9) in the placebo group. At week 52, the least squares mean change from baseline in NSAA total score was 1·46 (SE 0·43) for fordadistrogene movaparvovec and 1·37 (0·65) for placebo (difference between groups 0·09 [95% CI -1·46 to 1·64]; p=0·91). Adverse events occurred in 78 (99%) of 79 participants in the fordadistrogene movaparvovec group versus 27 (77%) of 35 in the placebo group. The most common adverse events in the fordadistrogene movaparvovec group versus the placebo group were vomiting (60 [76%] vs five [14%]), pyrexia (49 [62%] vs three [9%]), decreased appetite (26 [33%] vs one [3%]), nausea (23 [29%] vs three [9%]), increased liver glutamate dehydrogenase (19 [24%] vs zero), nasopharyngitis (19 [24%] vs six [17%]), and abdominal pain (17 [22%] vs three [9%]). Serious adverse events occurred in 25 (32%) participants in the fordadistrogene movaparvovec group versus five (14%) in the placebo group. There were no deaths in the study. INTERPRETATION: The study did not meet its primary efficacy endpoint. Based on the efficacy and safety data from this phase 3 study, the benefit-risk profile of fordadistrogene movaparvovec was determined to be negative. Thus, the study sponsor has discontinued any further clinical development of this investigational gene therapy agent. FUNDING: Pfizer.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Muntoni F, Nascimento A, Shin J, et al. Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study. Lancet Neurol. 2026. PMID: 41722591. doi:10.1016/S1474-4422(26)00036-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。